S M Blaney

Summary

Affiliation: Baylor College of Medicine
Country: USA

Publications

  1. ncbi request reprint Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015)
    Susan M Blaney
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, TX, USA
    J Clin Oncol 22:4804-9. 2004
  2. ncbi request reprint Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001)
    Susan M Blaney
    Texas Children s Cancer Center, 6621 Fannin, CC 1410 00, Houston, TX 77030, USA
    J Clin Oncol 23:525-31. 2005
  3. ncbi request reprint Intrathecal mafosfamide: a preclinical pharmacology and phase I trial
    Susan M Blaney
    Texas Children s Cancer Center, 6621 Fannin St, CC 1410 00, Houston, TX 77030 2399, USA
    J Clin Oncol 23:1555-63. 2005
  4. ncbi request reprint Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis
    Susan M Blaney
    Texas Children s Cancer Center Baylor College of Medicine, Houston, TX 77030, USA
    J Clin Oncol 21:143-7. 2003
  5. ncbi request reprint Neoplastic meningitis: diagnosis and treatment considerations
    S M Blaney
    Hematology Oncology Section, Department of Pediatrics, Baylor College of Medicine and Texas Children s Cancer Center and Hematology Service, Houston, TX 77030 2399, USA
    Med Oncol 17:151-62. 2000
  6. ncbi request reprint A phase I study of irinotecan in pediatric patients: a pediatric oncology group study
    S Blaney
    Texas Children s Cancer Center Baylor College of Medicine, Houston 77030, USA
    Clin Cancer Res 7:32-7. 2001
  7. ncbi request reprint Influence of phenytoin on the disposition of irinotecan: a case report
    Daryl J Murry
    Texas Children s Cancer Center Baylor College of Medicine, Houston, USA
    J Pediatr Hematol Oncol 24:130-3. 2002
  8. ncbi request reprint Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group
    Suman Malempati
    Department of Pediatrics, Oregon Health and Science University, Portland, OR 97239 3098, USA
    J Clin Oncol 25:1505-11. 2007
  9. ncbi request reprint Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers
    S L Berg
    Texas Children s Cancer Center, Texas Children s Hospital and Baylor College of Medicine, Houston 77030, USA
    J Clin Oncol 16:181-6. 1998
  10. ncbi request reprint The development of camptothecin analogs in childhood cancers
    L Bomgaars
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, Texas, USA
    Oncologist 6:506-16. 2001

Research Grants

  1. PEDIATRIC BRAIN TUMOR RESEARCH CENTER
    Susan Blaney; Fiscal Year: 2003

Detail Information

Publications78

  1. ncbi request reprint Phase I study of the proteasome inhibitor bortezomib in pediatric patients with refractory solid tumors: a Children's Oncology Group study (ADVL0015)
    Susan M Blaney
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, TX, USA
    J Clin Oncol 22:4804-9. 2004
    ..To determine the maximum-tolerated dose, dose-limiting toxicity (DLT), and pharmacodynamics of the proteasome inhibitor bortezomib (formerly PS-341) in children with recurrent or refractory solid tumors...
  2. ncbi request reprint Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001)
    Susan M Blaney
    Texas Children s Cancer Center, 6621 Fannin, CC 1410 00, Houston, TX 77030, USA
    J Clin Oncol 23:525-31. 2005
    ....
  3. ncbi request reprint Intrathecal mafosfamide: a preclinical pharmacology and phase I trial
    Susan M Blaney
    Texas Children s Cancer Center, 6621 Fannin St, CC 1410 00, Houston, TX 77030 2399, USA
    J Clin Oncol 23:1555-63. 2005
    ..A phase I and pharmacokinetic study of IT mafosfamide was performed to determine a dose for subsequent phase II trials...
  4. ncbi request reprint Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis
    Susan M Blaney
    Texas Children s Cancer Center Baylor College of Medicine, Houston, TX 77030, USA
    J Clin Oncol 21:143-7. 2003
    ..A phase I trial of intrathecal (IT) topotecan was performed to determine the optimal dose, the dose-limiting toxic effects, and the incidence and severity of other toxic effects in patients 3 years and older with neoplastic meningitis...
  5. ncbi request reprint Neoplastic meningitis: diagnosis and treatment considerations
    S M Blaney
    Hematology Oncology Section, Department of Pediatrics, Baylor College of Medicine and Texas Children s Cancer Center and Hematology Service, Houston, TX 77030 2399, USA
    Med Oncol 17:151-62. 2000
    ..This article provides an overview of the approaches to the diagnosis, evaluation, and treatment of neoplastic meningitis...
  6. ncbi request reprint A phase I study of irinotecan in pediatric patients: a pediatric oncology group study
    S Blaney
    Texas Children s Cancer Center Baylor College of Medicine, Houston 77030, USA
    Clin Cancer Res 7:32-7. 2001
    ..In conclusion, the recommended Phase II dose of irinotecan administered as a 60-min i.v. infusion daily for 5 days, every 21 days, is 39 mg/m2 in heavily treated and 50 mg/m2 in less-heavily treated children with solid tumors...
  7. ncbi request reprint Influence of phenytoin on the disposition of irinotecan: a case report
    Daryl J Murry
    Texas Children s Cancer Center Baylor College of Medicine, Houston, USA
    J Pediatr Hematol Oncol 24:130-3. 2002
    ..Further detailed pharmacokinetic studies of irinotecan in patients receiving concomitant therapy with enzyme-inducing anticonvulsants are required so that rational dosing recommendations can be provided for this patient population...
  8. ncbi request reprint Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: the Children's Oncology Group
    Suman Malempati
    Department of Pediatrics, Oregon Health and Science University, Portland, OR 97239 3098, USA
    J Clin Oncol 25:1505-11. 2007
    ..The purpose of this study was to determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLTs), and pharmacokinetic properties of pemetrexed in children...
  9. ncbi request reprint Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers
    S L Berg
    Texas Children s Cancer Center, Texas Children s Hospital and Baylor College of Medicine, Houston 77030, USA
    J Clin Oncol 16:181-6. 1998
    ....
  10. ncbi request reprint The development of camptothecin analogs in childhood cancers
    L Bomgaars
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, Texas, USA
    Oncologist 6:506-16. 2001
    ..These and future planned studies of this novel class of cytotoxic agents are critical to defining the ultimate role of topoisomerase I poisons in the treatment of childhood cancer...
  11. ncbi request reprint A phase I study of irinotecan administered on a weekly schedule in pediatric patients
    L Bomgaars
    Texas Children s Cancer Center Baylor College of Medicine, Houston, TX 77030, USA
    Pediatr Blood Cancer 46:50-5. 2006
    ..The objectives of this study were to determine the maximum tolerated dose (MTD), dose-limiting toxicities (DLTs), pharmacokinetics, and anti-tumor effect of irinotecan in pediatric patients with recurrent or refractory malignancies...
  12. pmc Synergy of karenitecin and mafosfamide in pediatric leukemia, medulloblastoma, and neuroblastoma cell lines
    Eufemia Jacob
    Texas Children s Cancer Center, Texas Children s Hospital, Baylor College of Medicine, Houston, Texas, USA
    Pediatr Blood Cancer 50:757-60. 2008
    ..The purpose of this study was to determine the cytotoxic effects of karenitecin and mafosfamide in vitro against leukemia, medulloblastoma, and neuroblastoma cell lines...
  13. ncbi request reprint Phase II trial of pyrazoloacridine in children with solid tumors: a Pediatric Oncology Group phase II study
    S L Berg
    Texas Children s Cancer Center, Houston 77030, USA
    J Pediatr Hematol Oncol 22:506-9. 2000
    ..The Pediatric Oncology Group conducted a phase II study to determine the activity of PZA administered as a 3-hour infusion...
  14. ncbi request reprint Intrathecal chemotherapy
    J Z Kerr
    Baylor College of Medicine, Texas Children's Cancer Center, 6621 Fannin, MC3-3320, Houston, TX 77030, USA
    Crit Rev Oncol Hematol 37:227-36. 2001
    ....
  15. ncbi request reprint Valproic Acid prolongs survival time of severe combined immunodeficient mice bearing intracerebellar orthotopic medulloblastoma xenografts
    Qin Shu
    Laboratory of Molecular Neuro Oncology, Texas Children s Cancer Center, Texas Children s Hospital, Houston, 77030, USA
    Clin Cancer Res 12:4687-94. 2006
    ..To develop novel orthotopic xenograft models of medulloblastoma in severe combined immunodeficient mice and to evaluate the in vivo antitumor efficacy of valproic acid...
  16. ncbi request reprint Plasma and cerebrospinal fluid pharmacokinetics of clofarabine in nonhuman primates
    Stacey L Berg
    Texas Children s Cancer Center, Department of Surgery, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 11:5981-3. 2005
    ..We studied the pharmacokinetics and cerebrospinal fluid penetration of clofarabine in a nonhuman primate model...
  17. ncbi request reprint Pharmacokinetics of phenylacetate administered as a 30-min infusion in children with refractory cancer
    Patrick Thompson
    Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
    Cancer Chemother Pharmacol 52:417-23. 2003
    ..We performed a pharmacokinetic study, as part of a phase I trial, of PAA in children with refractory cancer...
  18. ncbi request reprint Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates
    Stacey L Berg
    Texas Children s Cancer Center, 6621 Fannin Street, MC3 3320, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 59:743-7. 2007
    ..We therefore studied the CSF penetration of nelarabine and ara-G in a nonhuman primate model that has been highly predictive of anticancer drug distribution in humans...
  19. ncbi request reprint Plasma and cerebrospinal fluid pharmacokinetics of pemetrexed after intravenous administration in non-human primates
    Stacie L Stapleton
    Texas Children s Cancer Center, Baylor College of Medicine, 6621 Fannin, CC 1410 00, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 59:461-6. 2007
    ..We studied the plasma and cerebrospinal fluid (CSF) pharmacokinetics of pemetrexed in a non-human primate model that is highly predictive of human CSF penetration...
  20. ncbi request reprint Phase I trial of irofulven (MGI 114) in pediatric patients with solid tumors
    Lisa R Bomgaars
    Texas Children s Cancer Center Baylor College of Medicine, Houston, Texas 77030, USA
    Pediatr Blood Cancer 47:163-8. 2006
    ....
  21. ncbi request reprint Plasma and cerebrospinal fluid pharmacokinetics of valproic acid after oral administration in non-human primates
    Stacie L Stapleton
    Texas Children s Cancer Center Baylor College of Medicine, 6621 Fannin, CC 1410 00, Houston, TX, 77030, USA
    Cancer Chemother Pharmacol 61:647-52. 2008
    ....
  22. pmc Phase 1 study of valproic acid in pediatric patients with refractory solid or CNS tumors: a children's oncology group report
    Jack M Su
    Texas Children s Cancer Center, Texas Children s Hospital, Houston, Texas, USA
    Clin Cancer Res 17:589-97. 2011
    ..Secondary objectives included assessment of free and total VPA pharmacokinetics (PKs) and histone acetylation in peripheral blood mononuclear cells (PBMC) at steady state...
  23. pmc Reasons for participation in optional pharmacokinetic studies in children with cancer: a Children's Oncology Group phase 1 consortium study
    Stacey L Berg
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Pediatr Blood Cancer 55:119-22. 2010
    ..In the Children's Oncology Group (COG) Phase 1 Consortium, pharmacokinetic studies are usually optional. We surveyed the attitudes towards PK studies among subjects in phase 1 trials at COG institutions...
  24. pmc Poly(ADP-ribose) polymerase inhibitor ABT-888 potentiates the cytotoxic activity of temozolomide in leukemia cells: influence of mismatch repair status and O6-methylguanine-DNA methyltransferase activity
    Terzah M Horton
    Texas Children s Cancer Center Baylor College of Medicine, Houston, Texas 77030, USA
    Mol Cancer Ther 8:2232-42. 2009
    ..In conclusion, although ABT-888 potentiation of TMZ was most pronounced in MMR-deficient cells with low MGMT activity, neither MMR proficiency nor MGMT overexpression completely abrogated ABT-888 potentiation of TMZ...
  25. doi request reprint Plasma and cerebrospinal fluid pharmacokinetics of tasidotin (ILX-651) and its metabolites in non-human primates
    Lindsay B Kilburn
    Texas Children s Cancer Center, Baylor College of Medicine, 6621 Fannin St, MC 3 3320, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 64:335-40. 2009
    ..To evaluate the plasma and cerebrospinal fluid (CSF) pharmacokinetics and CSF penetration of tasidotin and metabolites in a nonhuman primate model...
  26. pmc Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study
    Elizabeth A Raetz
    Department of Pediatrics, New York University, School of Medicine, Hassenfeld Children s Center for Cancer and Blood Disorders, New York, NY 10016, USA
    J Clin Oncol 26:3756-62. 2008
    ....
  27. doi request reprint Pharmacokinetics of irinotecan and its metabolites in pediatric cancer patients: a report from the children's oncology group
    Patrick A Thompson
    Texas Children s Cancer Center and Hematology Service, Texas Children s Hospital, Baylor College of Medicine, 6621 Fannin St 1510 00, Houston, TX 77030 2399, USA
    Cancer Chemother Pharmacol 62:1027-37. 2008
    ..To develop a population pharmacokinetic model of irinotecan and its major metabolites in children with cancer and to identify covariates that predict variability in disposition...
  28. ncbi request reprint Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study
    Terzah M Horton
    Texas Children s Cancer Center Baylor College of Medicine, Houston, TX 77030, USA
    J Clin Oncol 25:4922-8. 2007
    ..To determine the tolerability, pharmacokinetics, and mechanisms of temozolomide resistance in children with relapsed or refractory leukemia...
  29. pmc Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report
    Stacey L Berg
    Texas Children s Cancer Center, 6621 Fannin St, MC3 3320, Houston, TX 77030, USA
    J Clin Oncol 29:316-23. 2011
    ....
  30. ncbi request reprint Phase II trial of irinotecan in children with refractory solid tumors: a Children's Oncology Group Study
    Lisa R Bomgaars
    Baylor College of Medicine, Houston, TX, USA
    J Clin Oncol 25:4622-7. 2007
    ..A phase II study was performed to determine the efficacy of irinotecan (IRN) in children with refractory solid tumors. Secondary objectives were to evaluate toxicity, pharmacokinetics, pharmacodynamics, and UGT1A1 genotype...
  31. ncbi request reprint A phase II window trial of procarbazine and topotecan in children with high-grade glioma: a report from the children's oncology group
    Murali M Chintagumpala
    Baylor College of Medicine, 6621 Fannin, CC 1510 00, Houston, TX, USA
    J Neurooncol 77:193-8. 2006
    ..Future trials should consider strategies to overcome the resistance mechanisms in children with high-grade glioma...
  32. ncbi request reprint Bortezomib interactions with chemotherapy agents in acute leukemia in vitro
    Terzah M Horton
    Texas Children s Cancer Center Baylor College of Medicine, 6621 Fannin, MC 3 3320, Houston, 77030, USA
    Cancer Chemother Pharmacol 58:13-23. 2006
    ..These data suggest bortezomib could potentiate the cytotoxic effects of combination chemotherapy in patients with leukemia...
  33. ncbi request reprint A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemia: a Children's Oncology Group study
    Terzah M Horton
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Clin Cancer Res 13:1516-22. 2007
    ..A phase 1 study to determine the maximum-tolerated dose, dose-limiting toxicity, pharmacokinetics, and biological effects of bortezomib in children with recurrent/refractory leukemia...
  34. ncbi request reprint Plasma and cerebrospinal fluid pharmacokinetics of rebeccamycin (NSC 655649) in nonhuman primates
    Stacey L Berg
    Texas Children s Cancer Center, Department of Pediatrics, Baylor College of Medicine, 6621 Fannin, MC 33320, Houston 77030, USA
    Cancer Chemother Pharmacol 54:127-30. 2004
    ..We studied the plasma and cerebrospinal fluid (CSF) pharmacokinetics of NSC 655649 after systemic administration in a nonhuman primate model that is predictive of anticancer drug behavior in humans...
  35. ncbi request reprint Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates
    Kathleen Neville
    Texas Children s Cancer Center, Houston, 77030, USA
    Clin Cancer Res 10:2525-9. 2004
    ..We used a nonhuman primate model that is highly predictive of the cerebrospinal fluid penetration of drugs in humans to study the pharmacokinetics of imatinib in plasma and cerebrospinal fluid (CSF) after i.v. and p.o. administration...
  36. ncbi request reprint Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates
    Stacey L Berg
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 54:85-8. 2004
    ..We studied the plasma and cerebrospinal fluid (CSF) pharmacokinetics of depsipeptide in a nonhuman primate model that is highly predictive of human CSF penetration...
  37. ncbi request reprint Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group
    Stacey L Berg
    Texas Children s Cancer Center, Baylor College of Medicine, 6621 Fannin St, MC3 3320, Houston, TX 77030, USA
    J Clin Oncol 23:3376-82. 2005
    ..We sought to define the response rate of nelarabine in children and young adults with refractory or recurrent T-cell disease...
  38. ncbi request reprint Plasma and cerebrospinal fluid pharmacokinetic study of BNP1350 in nonhuman primates
    Patrick A Thompson
    Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 53:527-32. 2004
    ..This study was undertaken to define the pharmacokinetics of BNP1350 in both plasma and cerebrospinal fluid (CSF) in a nonhuman primate model...
  39. ncbi request reprint Phase I trial and pharmacokinetic study of raltitrexed in children with recurrent or refractory leukemia: a pediatric oncology group study
    Terzah M Horton
    University of Texas Health Science Center, San Antonio, TX, USA
    Clin Cancer Res 11:1884-9. 2005
    ..To evaluate the toxicity, antileukemic activity, and pharmacology of raltitrexed administered weekly for 3 weeks to patients with refractory or recurrent leukemia...
  40. ncbi request reprint Phase I and pharmacokinetic study of thalidomide with carboplatin in children with cancer
    Murali Chintagumpala
    Texas Children s Cancer Center, 6621 Fannin, MC 3 3320, Houston, TX 77030, USA
    J Clin Oncol 22:4394-400. 2004
    ..Recent studies have indicated that thalidomide inhibits angiogenesis. We performed a phase I and pharmacokinetic study of thalidomide with carboplatin in children with refractory solid tumors...
  41. ncbi request reprint Incorporation of an enrichment program into a study protocol involving long-term restraint in macaques
    Leticia H McGuffey
    Texas Children s Cancer Center, Baylor College of Medicine, Houston 77030, USA
    Lab Anim (NY) 31:37-9. 2002
    ..In an attempt to minimize such stress, the authors describe an enrichment program they designed for use with restrained adult male rhesus macaques...
  42. ncbi request reprint Treatment controversies in medulloblastoma
    M Chintagumpala
    Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas 77030, USA
    Curr Opin Oncol 13:154-9. 2001
    ..In this article, we review the clinical and biologic prognostic factors for classifying medulloblastoma, current strategies for the management of this disease, and potential strategies to prevent or minimize long-term treatment sequelae...
  43. ncbi request reprint Phase I trial of intrathecal liposomal cytarabine in children with neoplastic meningitis
    L Bomgaars
    Texas Children s Cancer Center Baylor College of Medicine, 6621 Fannin, MC 3 3320, Houston, TX 77030, USA
    J Clin Oncol 22:3916-21. 2004
    ....
  44. ncbi request reprint Immunonanoshells for targeted photothermal ablation in medulloblastoma and glioma: an in vitro evaluation using human cell lines
    Ronald J Bernardi
    Texas Children s Cancer Center, Texas Children s Hospital, Baylor College of Medicine, Houston, TX, USA
    J Neurooncol 86:165-72. 2008
    ....
  45. ncbi request reprint Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis
    Ronald J Bernardi
    Texas Children s Hospital, Baylor College of Medicine, Houston, TX, 77030, USA
    Cancer Chemother Pharmacol 62:355-61. 2008
    ....
  46. doi request reprint Direct orthotopic transplantation of fresh surgical specimen preserves CD133+ tumor cells in clinically relevant mouse models of medulloblastoma and glioma
    Qin Shu
    Laboratory of Molecular Neuro Oncology, Texas Children s Cancer Center, Texas Children s Hospital, 6621 Fannin St, MC 3 3320, Houston, Texas 77030, USA
    Stem Cells 26:1414-24. 2008
    ..Disclosure of potential conflicts of interest is found at the end of this article...
  47. pmc Plasma and cerebrospinal fluid pharmacokinetics of ABT-888 after oral administration in non-human primates
    Jodi A Muscal
    Texas Children s Cancer Center, Baylor College of Medicine, and Texas Children s Hospital, 6621 Fannin Street, MC3 3320, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 65:419-25. 2010
    ..We studied the plasma and cerebrospinal fluid (CSF) pharmacokinetics (PK) of ABT-888 in a non-human primate (NHP) model that is highly predictive of human CSF penetration...
  48. ncbi request reprint Valproic acid induces growth arrest, apoptosis, and senescence in medulloblastomas by increasing histone hyperacetylation and regulating expression of p21Cip1, CDK4, and CMYC
    Xiao Nan Li
    Laboratory of Molecular Neurooncology, Texas Children s Hospital, Baylor College of Medicine, Houston, TX 77030, USA
    Mol Cancer Ther 4:1912-22. 2005
    ..Therefore, valproic acid may represent a novel therapeutic option in medulloblastoma treatment...
  49. doi request reprint Plasma and cerebrospinal fluid pharmacokinetics of MP470 in non-human primates
    P A Baxter
    Texas Children s Cancer Center, Baylor College of Medicine, 6621 Fannin St, CCC1400 00, Houston, TX 77030, USA
    Cancer Chemother Pharmacol 67:809-12. 2011
    ..The plasma and cerebrospinal fluid (CSF) pharmacokinetics of MP470 were studied in a non-human primate model that is highly predictive of CSF penetration in humans...
  50. ncbi request reprint Differential expression of survivin splice isoforms in medulloblastomas
    X N Li
    Laboratory of Molecular Neurooncology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Neuropathol Appl Neurobiol 33:67-76. 2007
    ....
  51. ncbi request reprint Methotrexate pharmacokinetics in infants with acute lymphoblastic leukemia
    Patrick A Thompson
    Texas Children s Cancer Center, Baylor College of Medicine, 6621 Fannin St MC, Houston, TX 77030 2399, USA
    Cancer Chemother Pharmacol 59:847-53. 2007
    ....
  52. ncbi request reprint Expression analysis of juvenile pilocytic astrocytomas by oligonucleotide microarray reveals two potential subgroups
    Kwong Kwok Wong
    Texas Children s Cancer Center, Baylor College of Medicine, Houston, TX 77030, USA
    Cancer Res 65:76-84. 2005
    ..Immunostaining of myelin basic protein on paraffin sections derived from 18 incompletely resected JPAs suggests that JPA without myelin basic protein-positively stained tumor cells may have a higher tendency to progress...
  53. ncbi request reprint Leptomeningeal cancer in the pediatric patient
    Kathleen A Neville
    Texas Children s Cancer Center, Baylor College of Medicine Houston, TX 77030, USA
    Cancer Treat Res 125:87-106. 2005
    ..Further research is critical to identify new therapeutic strategies for children with or at high risk for leptomeningeal cancer...
  54. ncbi request reprint Phase I Trial of G3139, a bcl-2 antisense oligonucleotide, combined with doxorubicin and cyclophosphamide in children with relapsed solid tumors: a Children's Oncology Group Study
    Susan R Rheingold
    Children s Hospital of Philadelphia, Philadelphia, PA 19104, USA
    J Clin Oncol 25:1512-8. 2007
    ..To determine the maximum-tolerated dose, toxicity, pharmacokinetics, and biologic effects of G3139 when administered with doxorubicin and cyclophosphamide to children with relapsed solid tumors...
  55. ncbi request reprint Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children's Oncology Group Study
    Najat C Daw
    Department of Hematology Oncology, Mail Stop 260, St Jude Children s Research Hospital, 332 N Lauderdale, Memphis, TN 38105 2794, USA
    J Clin Oncol 23:6172-80. 2005
    ..Epidermal growth factor receptor is expressed in pediatric malignant solid tumors. We conducted a phase I trial of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in children with refractory solid tumors...
  56. doi request reprint Characteristics and outcome of pediatric patients enrolled in phase I oncology trials
    Aerang Kim
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, 10 Center Drive, Building 10 CRC, Room 1 3872, Bethesda, MD 20892, USA
    Oncologist 13:679-89. 2008
    ..To describe the characteristics of pediatric subjects who enroll in phase I trials, to determine the associations between pre-enrollment characteristics and the risk for toxicity, and to analyze response and survival outcomes...
  57. ncbi request reprint Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a Pediatric Brain Tumor Consortium Study (PBTC-004)
    Sridharan Gururangan
    The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 12:1540-6. 2006
    ..San Ramon, CA) was conducted in children with neoplastic meningitis following recurrent primary brain tumors to describe toxicities, estimate the maximum tolerated dose (MTD), and document evidence of responses to this agent...
  58. pmc Pediatric phase I and pharmacokinetic study of erlotinib followed by the combination of erlotinib and temozolomide: a Children's Oncology Group Phase I Consortium Study
    Regina I Jakacki
    Children s Hospital of Pittsburgh, Pittsburgh, PA 15213, USA
    J Clin Oncol 26:4921-7. 2008
    ..We conducted a phase I and pharmacokinetic study of the epidermal growth factor receptor (EGFR) inhibitor erlotinib as a single agent and in combination with temozolomide in children with refractory solid tumors...
  59. ncbi request reprint Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors
    Abdul Kader Souid
    Department of Pediatric Hematology Oncology, State University of New York Upstate Medical University, Syracuse, New York 13210, USA
    Clin Cancer Res 9:703-10. 2003
    ..This Phase I study was designed primarily to determine the maximum tolerated dose (MTD) and dose-limiting toxicities (DLTs) of irinotecan and cisplatin with and without amifostine in children with refractory solid tumors...
  60. pmc A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood
    Regina I Jakacki
    Children s Hospital of Pittsburgh, Pittsburgh, PA 15213, USA
    Neuro Oncol 10:569-76. 2008
    ..Radiographic changes following RT make determination of early tumor progression difficult. Metastatic disease is common prior to death...
  61. ncbi request reprint Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors
    Antonio Jimeno
    Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland 21231 1000, and Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN, USA
    Pediatr Blood Cancer 49:352-7. 2007
    ..Gefitinib did not induce any significant variation in the levels of the assessed parameters, and none of these determinations showed significant predictive or prognostic value...
  62. ncbi request reprint Pharmacokinetics of intrathecal gemcitabine in nonhuman primates
    Merrill J Egorin
    Department of Pharmacology, and Division of Hematology Oncology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213, USA
    Clin Cancer Res 8:2437-42. 2002
    ..We quantified cerebrospinal fluid (CSF) and plasma concentrations of gemcitabine and its inactive metabolite, 2',2'-difluorodeoxyuridine (dFdU), in nonhuman primates given intrathecal gemcitabine...
  63. ncbi request reprint Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas
    Brigitte C Widemann
    Pediatric Oncology Branch, National Cancer Institute, Bethesda, MD 20892, USA
    J Clin Oncol 24:507-16. 2006
    ....
  64. ncbi request reprint New approaches to drug development in pediatric oncology
    Peter C Adamson
    The Children s Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Cancer J 11:324-30. 2005
    ..The goal of these initiatives is to improve the overall outcome for childhood cancer while minimizing the short and long-term sequelae associated with current treatment strategies...
  65. pmc Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma
    Daphne A Haas-Kogan
    University of California, San Francisco, San Francisco, CA, USA
    Neuro Oncol 10:341-7. 2008
    ..The MTD of tipifarnib with concurrent radiation is 125 mg/m(2)/dose b.i.d. One-year survival and progression-free survival estimates are 36.4% (SE 16.7%) and 9.4% (SE 6.3%), respectively...
  66. ncbi request reprint Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children's Oncology Group report
    Maryam Fouladi
    Department of Hematology Oncology, St Jude Children s Research Hospital, Memphis, TN 38105 2794, USA
    J Clin Oncol 24:3678-85. 2006
    ..To determine the maximum-tolerated dose (MTD), dose-limiting toxicities (DLT), pharmacokinetic profile, and pharmacodynamics of the histone deacetylase inhibitor, depsipeptide, in children with refractory or recurrent solid tumors...
  67. doi request reprint Phase I trial of VNP40101M (Cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study
    Sridharan Gururangan
    The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center, Durham, North Carolina 27710, USA
    Clin Cancer Res 14:1124-30. 2008
    ..VNP40101M (Cloretazine), a novel DNA alkylating agent, was evaluated in a phase I study in children with recurrent brain tumors...
  68. ncbi request reprint A phase II trial of rebeccamycin analogue (NSC #655649) in children with solid tumors: a Children's Oncology Group study
    Anne Marie Langevin
    University of Texas Health Science Center, San Antonio, Texas, USA
    Pediatr Blood Cancer 50:577-80. 2008
    ....
  69. ncbi request reprint Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Cons
    Mark W Kieran
    Dana Farber Cancer Institute and Children s Hospital Boston, Boston, MA 02115, USA
    J Clin Oncol 25:3137-43. 2007
    ..Primary objectives were to estimate the maximum-tolerated dose (MTD) and to describe the dose-limiting toxicities (DLTs) and pharmacokinetics of lonafarnib. Farnesylation inhibition of HDJ-2 in peripheral blood was also measured...
  70. ncbi request reprint A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's Oncology Group study
    Brenda J Weigel
    University of Minnesota Cancer Center and Department of Pediatrics, University of Minnesota, Minneapolis, MN 55455, USA
    Clin Cancer Res 13:1789-93. 2007
    ..To determine the recommended phase 2 dose, dose-limiting toxicities (DLT), pharmacokinetic profile, and pharmacodynamics of the heat shock protein (Hsp) 90 inhibitor, 17-allylaminogeldanamycin (17-AAG)...
  71. pmc Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report
    Ian F Pollack
    Department of Neurosurgery, Children s Hospital of Pittsburgh, 3705 Fifth Avenue, Pittsburgh, PA 15213, USA
    Neuro Oncol 9:145-60. 2007
    ..Imatinib may increase the risk of ITH, although the incidence of spontaneous hemorrhages in brainstem glioma is sufficiently high that this should be considered in studies of agents in which hemorrhage is a concern...
  72. ncbi request reprint Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosome-positive leukemia: results from a Children's Oncology Group phase 1 study
    Martin A Champagne
    Hopital Sainte Justine, 3175 Cote Ste Catherine, Montreal, QC, Canada, H3T 1C5
    Blood 104:2655-60. 2004
    ..Doses of 260 and 340 mg/m(2) provide systemic exposures similar to those of adults who are treated with daily doses of 400 and 600 mg, respectively...
  73. ncbi request reprint A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study
    Mason Bond
    B C Children s Hospital, Vancouver, British Columbia, Canada
    Pediatr Blood Cancer 50:254-8. 2008
    ..A phase II study of imatinib in children and young adults with select solid tumors was performed...
  74. pmc Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma
    Elizabeth Fox
    Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
    Blood 111:566-73. 2008
    ..15 mg/kg per day. The response rate in children with relapsed APL is similar to the response rate in adults. This trial was registered as #NCT00020111 at www.ClinicalTrials.gov...
  75. ncbi request reprint Phase II study of oxaliplatin in children with recurrent or refractory medulloblastoma, supratentorial primitive neuroectodermal tumors, and atypical teratoid rhabdoid tumors: a pediatric brain tumor consortium study
    Maryam Fouladi
    St Jude Children s Research Hospital, Memphis, Tennessee 38105 2794, USA
    Cancer 107:2291-7. 2006
    ....
  76. doi request reprint Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study
    Julia L Glade Bender
    College of Physicians and Surgeons of Columbia University, New York, NY, USA
    J Clin Oncol 26:399-405. 2008
    ..Primary aims included estimating the maximum-tolerated dose (MTD) and determining the dose-limiting toxicities (DLTs), pharmacokinetics, and biologic effects of BV in children with cancer...
  77. ncbi request reprint Topotecan by 21-day continuous infusion in children with relapsed or refractory solid tumors: a Children's Oncology Group study
    Douglas S Hawkins
    Children s Hospital and Regional Medical Center, Seattle, WA, USA
    Pediatr Blood Cancer 47:790-4. 2006
    ..The Children's Oncology Group conducted a phase II trial of 21-day continuous infusion topotecan to determine the response rate in pediatric patients with recurrent or refractory malignant solid tumors...
  78. ncbi request reprint Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study
    Denise M Adams
    Cincinnati Children s Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA
    Pediatr Blood Cancer 50:549-53. 2008
    ....

Research Grants1

  1. PEDIATRIC BRAIN TUMOR RESEARCH CENTER
    Susan Blaney; Fiscal Year: 2003
    ..It offers leadership in the development of new agents, in new uses of sophisticated radiotherapy, and in the application of new approaches to brain tumor therapy. ..